Valtech Cardio, a company out of Or Yehuda, Israel, has received European CE Mark to introduce its Cardioband annuloplasty system.
According to the company, the Cardioband system is a revolutionary percutaneous treatment for Mitral regurgitation (MR), based on surgical foundations.
MR is defined as an abnormal reversal of blood flow from the left ventricle to the left atrium, one of the two blood collection chambers of the heart.
Cardioband offers reconstruction of the mitral valve by direct annuloplasty delivered transfemorally with no need for open-heart surgery.
Amir Gross, founder and CEO of Valtechsais that the company is pleased to be able to introduce Cardioband to the European markets.
"Receipt of the CE Mark is the culmination of concerted and concentrated efforts by many individuals, and it is the result of productive collaboration with the medical community. We are confident that Cardioband will prove to be a meaningful addition to physician's available treatment options in addressing MR, providing a first-line mitral valve repair option that preserves the ability to perform future percutaneous or surgical valve repair and replacement," Gross said.
The surgical procedure is done endovascularly, without stopping the heart, and the actual valve leaflets and chordae are not touched during implantation.